Loss of weight

by Medindia Content Team on  April 3, 2002 at 4:06 PM General Health News
RSS Email Print This Page Comment
Font : A-A+

Loss of weight
The European Medicines Evaluation Agency (EMEA) committee that its scientific committee had initiated a review on the risks and benefits of the anti-obesity drug sibutramine. The drug is sold as Reductil in Europe and Meridia in the United States.

The drug was temporarily withdrawn from the market in Italy after reports that two patients taking the drug had died. A spokesman declined to say who was leading the review, which was requested by Italy.

Abbott, the manufacturer of sibutramine, has said it is aware of 34 deaths globally in patients taking the drug, but insists there is no evidence that the drug was the cause of the deaths.Millions of patients have taken the drug since it was launched in 1997.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Height and Weight-Kids 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive